Multiple Myeloma Clinical Trials
A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 611 clinical trials
Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM
As optimal tolerance is the key for developing new treatments for the very elderly population, the aim of the study is to compare the efficacy and tolerance of isatuximab in combination with lenalidomide+dexamethasone (Rd) versus Rd only in very elderly patients aged 70 years or older. ln sum, a clear …
- 0 views
- 23 May, 2022
- 8 locations
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453
- 0 views
- 03 Jun, 2022
A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma
extramedullary multiple myeloma, and the pharmacokinetics of Selinexor and CT103A Kinetic and pharmacodynamic characteristics.
- 0 views
- 05 Jun, 2022
- 1 location
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused ABBV-383 of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Multiple myeloma (MM) is an incurable disease characterized by the growth of monoclonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in
- 0 views
- 25 Jul, 2022
- 5 locations
A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
in elderly patients with multiple myeloma at first relapse . The patient population will consist of adult men and women more than 70 years, who meet eligibility criteria. Following the
- 0 views
- 22 Dec, 2021
- 6 locations
A Study of Evaluating the Safety and Efficacy of ATG-010 Bortezomib and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Refractory Multiple Myeloma (RRMM).
- 0 views
- 06 Oct, 2021
- 28 locations
Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM
refractory multiple myeloma.
- 0 views
- 22 Mar, 2022
- 1 location
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
the RP2Ds. Pharmacokinetics (PK), immunogenicity, and the anti-multiple myeloma activity of EMB-06 will also be assessed.
- 6 views
- 14 May, 2022
- 6 locations
EFC15951 - SC versus IV isatuximab in combination with pomalidomide and dexamethasone in RRMM
This is a randomized, multicenter, Phase 3, open-label study evaluatingsubcutaneous (SC) vs intravenous (IV) administration of isatuximab incombination with pomalidomide and dexamethasone (Pd) in RRMM patients(study participants) who have received at least 1 prior line of therapy includinglenalidomide and a proteasome inhibitor (PI). Eligible participants will berandomized 1:1 into 1 …
- 0 views
- 09 Aug, 2022
Integrin 7 BCMA CS1 CD38 and CD138 as the Single or Compound Targets for the Fourth Genenation of CAR-T Cells
According to the high expression of tumor cell-associated antigen CD138, integrin 7, CS1, CD38 and BCMA in patients with refractory/recurrent multiple myeloma, the fourth generation of CAR-T
- 0 views
- 26 Jan, 2021
- 3 locations